David Sinclair describes a research path focused on cellular rejuvenation. In his lab, AI, visualization, and machine learning are used to understand how skin cells from very old humans could be shifted back toward a much younger biological state.
What is changing
Since 2017, the team has been working to bring the cost of the technology down. Sinclair highlights small molecules as the cheapest route, potentially manufacturable for only a few cents per pill, compared with more complex viral approaches.
What to watch
- ER100 is mentioned as a viral candidate moving toward human use.
- The dosing window discussed is short: about six weeks.
- Billions of molecules are being screened mostly in silico with artificial intelligence.
- A molecular cocktail already exists as a proof of concept and may move into a human clinical trial in the coming months as part of the X Prize.
The practical signal is significant: if the approach works in humans, longevity research could move closer to a faster, measurable, and potentially affordable intervention.
Source
- Chaîne: Peter H. Diamandis
- Vidéo source: https://www.youtube.com/shorts/ORG0tkhyiBA
No comments yet